SCR-LIP-000493 · Claim · machine-readable JSON →

This scoping review of lipedema treatments (2020-2025) identified zero eligible studies on pharmacological treatment, with gestrinone not mentioned among any evaluated or proposed drug therapies (selenium, butcher's broom, diosmin, metformin, exenatide).

This single-paper claim was consolidated into general propositions (R-CLM-19); its evidence now sits under:

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
very low (GRADE)
Evidence
1 source(s)
Dates
2026-11-17 → 2026-11-17

Structured evidence, machine-compiled — not a verdict.

Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-11-17

Evidence over time

2026Treatment Strategies for Lipedema: A Scoping Review on liposuction, compression therapy, bariatric surgery and pharmacological treatment (2026) · conflicting

Evidence (1)

Context (PECO)

Populationpatients with lipedema
Conditionlipedema
Exposurepharmacological treatment (no gestrinone identified)
Outcomesymptom relief, volume reduction, QoL
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Auto-ingested single source; not yet human-reviewed.

Change log